Get the Stockscreener App
25.75
2.14%
0.54
After Hours:
26.00
0.25
+0.97%
Schrodinger Inc stock is traded at $25.75, with a volume of 1.14M.
It is up +2.14% in the last 24 hours and up +8.51% over the past month.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
See More
Previous Close:
$25.21
Open:
$25.02
24h Volume:
1.14M
Relative Volume:
1.00
Market Cap:
$1.94B
Revenue:
$193.35M
Net Income/Loss:
$-177.58M
P/E Ratio:
-10.51
EPS:
-2.45
Net Cash Flow:
$-172.43M
1W Performance:
+33.98%
1M Performance:
+8.51%
6M Performance:
+46.39%
1Y Performance:
+2.84%
1-Day Range:
$24.57
$25.85
1-Week Range:
$19.52
$26.86
52-Week Range:
$16.60
$28.47
Schrodinger Inc Stock (SDGR) Company Profile
Name
Schrodinger Inc
Sector
Industry
Phone
503-299-1150
Address
1540 BROADWAY, NEW YORK, NY
Compare SDGR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
25.75 | 1.94B | 193.35M | -177.58M | -172.43M | -2.45 |
|
VEEV
Veeva Systems Inc
|
215.95 | 36.39B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
53.21 | 9.87B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
40.45 | 7.46B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
84.52 | 7.21B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.45 | 6.30B | 906.14M | -52.62M | 89.62M | -0.3621 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-05-23 | Resumed | Piper Sandler | Overweight |
| Dec-19-22 | Initiated | Goldman | Neutral |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-11-21 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-13-21 | Initiated | Berenberg | Buy |
| Sep-01-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-25-21 | Initiated | Craig Hallum | Buy |
| Nov-23-20 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-02-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-02-20 | Initiated | Jefferies | Hold |
| Mar-02-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Schrodinger Inc Stock (SDGR) Latest News
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - 01net
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | SDGR Stock News - GuruFocus
Schrödinger (NASDAQ:SDGR) shareholders are up 29% this past week, but still in the red over the last five years - simplywall.st
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last? - MSN
Schrodinger price target raised to $32 from $30 at KeyBanc - TipRanks
Schrodinger’s Karen Akinsanya sells $419,570 in stock By Investing.com - Investing.com South Africa
Schrodinger’s Karen Akinsanya sells $419,570 in stock - Investing.com
Schrodinger issues statement on FDA phasing out animal testing requirement - TipRanks
FDA recent move marks paradigm shift in drug development, boosting Schrödinger (SDGR) and other biotech stocks - Investorsobserver
Schrodinger (SDGR) Backs FDA's Initiative to Cut Animal Testing in Drug Development | SDGR Stock News - GuruFocus
Schrödinger backs FDA’s move away from animal testing By Investing.com - Investing.com South Africa
Schrodinger to Launch Predictive Toxicology Tool in H2 - marketscreener.com
Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs - 01net
Schrödinger backs FDA’s move away from animal testing - Investing.com Australia
Schrödinger's Statement Regarding FDA Plan to Phase Out Animal T - GuruFocus
Schrödinger'S Statement Regarding FDA Plan To Phase Out Animal Testing Requirement For Monoclonal Antibodies And Other Drugs - MarketScreener
Vanguard Group Inc. Lowers Holdings in Schrödinger, Inc. (NASDAQ:SDGR) - MarketBeat
Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade) - Seeking Alpha
Schrödinger (SDGR) Reveals Promising Preclinical Data for Cancer Inhibitors - GuruFocus
Schrodinger Settles Lawsuit Over Director Compensations; Shares Up - MarketScreener
Schrödinger (SDGR) Faces Cash Burn Challenges Amid Growth - GuruFocus
Schrodinger settles director pay lawsuit, to reform governance By Investing.com - Investing.com South Africa
Schrodinger settles director pay lawsuit, to reform governance - Investing.com
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements - Benzinga
Schrodinger Stock Hits 52-Week Low at $16.64 Amid Market Challenges - Investing.com
Schrödinger, Inc. (NASDAQ:SDGR) Shares Purchased by Massachusetts Financial Services Co. MA - MarketBeat
Top 5 AI & Digital Biotech Companies (April 2025) - Securities.io
Swiss National Bank Has $2.41 Million Stock Position in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger (NASDAQ:SDGR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Schrödinger Finally Embraces AI – Is It a Buy? - Nanalyze
Schrödinger to Present at Four Investor Conferences in September - Business Wire
Schrödinger to Present Preclinical Data at AACR Annual Meeting - 01net
(SDGR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Schrodinger Inc (SDGR) Trading Down 1.72% on Mar 21 - GuruFocus.com
Schrodinger at KeyBanc Forum: Computational Drug Discovery Focus By Investing.com - Investing.com South Africa
Schrodinger at KeyBanc Forum: Computational Drug Discovery Focus - Investing.com India
(SDGR) Proactive Strategies - Stock Traders Daily
Proficio Capital Partners LLC Purchases Shares of 11,285 Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger adds Bridget van Kralingen to board By Investing.com - Investing.com Australia
Schrodinger at Leerink Global: Strategic Growth and Challenges - Investing.com India
Schrodinger appoints Bridget van Kralingen to board By Investing.com - Investing.com Canada
Schrödinger Appoints Bridget van Kralingen To Board - citybiz
Schrodinger appoints Bridget van Kralingen to board - Investing.com
Schrödinger adds Bridget van Kralingen to board - Investing.com India
Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen - Bakersfield.com
Schrodinger Inc (SDGR) Q4 2024: Everything You Need To Know Ahea - GuruFocus.com
Schrodinger Officer Sells Shares to Cover Tax Liability - TradingView
Schrodinger EVP & CFO sells shares worth $119,484 By Investing.com - Investing.com Australia
Schrodinger EVP & CFO sells shares worth $119,484 - Investing.com India
Schrodinger Inc Stock (SDGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):